By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617


SEARCH JOBS
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit www.biogenidec.com


Key Statistics


Email:
Ownership: Public

Web Site: Biogen Idec
Employees: 1700
Symbol: BIIB
 



Industry
Biotechnology


Collaborations

NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan Corporation PLC  (crohn's & MS)

Dyax Corp.  Antibody phage display





Company News
Biogen Idec (BIIB) And Swedish Orphan Biovitrum Announce Positive Top-Line Efficacy And Safety Results From Phase 3 ALPROLIX Pediatric Study 2/27/2015 10:28:34 AM
Biogen Idec (BIIB) To Present At The Cowen and Company 35th Annual Healthcare Conference 2/24/2015 10:37:28 AM
Biogen Idec (BIIB), Columbia University And Columbia University Identify New ALS Gene And Signaling Pathways 2/20/2015 1:13:46 PM
Biogen Idec (BIIB) To Present At The 2015 RBC Capital Markets’ Global Healthcare Conference 2/18/2015 1:37:47 PM
Biogen Idec (BIIB) Release: Developers #HackMS At The First Ever Hackathon For Multiple Sclerosis 2/10/2015 11:26:55 AM
Isis Pharmaceuticals, Inc. (ISIS) Earns $5 Million Milestone Payment From Biogen Idec (BIIB) 2/10/2015 7:37:47 AM
Regulus Therapeutics, Inc. (RGLS) Earns Milestone Payment From Biogen Idec (BIIB) Related To The Identification Of Potential Microrna Biomarkers In Multiple Sclerosis 2/2/2015 10:03:08 AM
Biogen Idec (BIIB) 2014 Revenues Increase 40% to $9.7 Billion 1/30/2015 11:32:11 AM
Biogen Idec (BIIB) to Hire 100 New Staffers for RTP Ops 1/30/2015 6:43:31 AM
Biogen Idec (BIIB), Fondazione Telethon And Ospedale San Raffaele Announce Global Collaboration To Develop Gene Therapies For Hemophilia 1/29/2015 10:35:29 AM
12345678910...
//-->